MicroTransponder
Series F in 2025
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Affineon
Seed Round in 2025
Affineon is a healthcare technology company that specializes in AI-driven inbox management. It automates the processing of routine and clinically insignificant lab results, reducing the workload for healthcare providers. The platform groups, analyzes, and trends lab results into concise summaries, including potential next steps and complete patient notes. It also routes non-urgent messages to staff, decreasing the number of messages providers need to attend to by up to 30%. This results in significant time savings, with providers gaining over five hours per week. Affineon seamlessly integrates with existing electronic health records (EHR) systems, ensuring providers can continue using their current workflows.
Prolocor
Convertible Note in 2024
Prolocor is a biotechnology company based in Philadelphia, PA, founded in 2020. It specializes in developing diagnostic tests aimed at assessing and managing cardiovascular disease risk. The company focuses on creating a precise method to quantify platelet FcγRIIa, which helps identify patients at varying risk levels for heart attacks, strokes, and cardiovascular-related deaths. Prolocor's tests utilize flow cytometry to measure the number of FcγRIIa molecules on platelets, enabling healthcare providers to optimize treatment strategies. This innovative approach aims to reduce complications such as bleeding and recurrent thrombotic events, enhancing patient care in cardiovascular health.
Worlds, Inc., established in 2018 and based in Dallas, Texas, specializes in spatial artificial intelligence (AI) solutions. The company's flagship product, SpatialSense, is a comprehensive platform that combines deep learning and IoT within a 4D environment. SpatialSense enables organizations to remotely monitor and analyze their physical spaces, providing insights into people, objects, and events. The platform includes modules for AI training, 3D modeling, spatial navigation, and AI bot creation. Worlds serves clients in military, healthcare, and energy sectors, helping them optimize their operations through real-world automation.
Validic
Venture Round in 2022
Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.
Prolocor
Seed Round in 2022
Prolocor is a biotechnology company based in Philadelphia, PA, founded in 2020. It specializes in developing diagnostic tests aimed at assessing and managing cardiovascular disease risk. The company focuses on creating a precise method to quantify platelet FcγRIIa, which helps identify patients at varying risk levels for heart attacks, strokes, and cardiovascular-related deaths. Prolocor's tests utilize flow cytometry to measure the number of FcγRIIa molecules on platelets, enabling healthcare providers to optimize treatment strategies. This innovative approach aims to reduce complications such as bleeding and recurrent thrombotic events, enhancing patient care in cardiovascular health.
MicroTransponder
Series E in 2022
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Genomenon
Series B in 2022
Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.
Alto is a transportation company that offers on-demand rides using a dedicated fleet of well-maintained and sanitized vehicles. Founded in 2018 and headquartered in Dallas, Texas, Alto employs a team of carefully vetted and trained drivers to ensure a professional and consistent riding experience for its members. The company focuses on providing customizable ride experiences, allowing customers to personalize various aspects of their journeys, such as music selection and climate control. By combining modern technology with a commitment to safety and service, Alto aims to simplify the process of booking private transportation for its users. The company began its operations in Dallas with plans to expand into additional U.S. cities.
Empirical Spine
Series B in 2021
Empirical Spine develops a stabilization system for orthopedics and spinal surgery, including LimiFlex, a paraspinous tension band that stabilizes the spine without compromising function for degenerative lumbar spinal disorders. Founded in 2015 and based in San Carlos, California, the company provides a minimally invasive flexion-restricting stabilization device designed to treat degenerative lumbar spinal disorders such as spinal stenosis with grade I degenerative spondylolisthesis, enabling secure spinal surgeries, supporting quicker recovery, and reducing long-term adjacent segment degeneration while preserving natural motion.
Avanta Risk Management
Seed Round in 2021
Avanta Risk Management offers financial management and consulting services. Data procurement, validation, and risk mitigation strategies exist within the financial services industry, ranging from nonexistent to more formal models. For inquiries, email, telephone numbers, and physical addresses are available on their website.
Genomenon
Series A in 2021
Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.
Noninvasix
Venture Round in 2021
Noninvasix, Inc., established in 2007, is a medical technology company based in Galveston, Texas. It develops non-invasive precision oximetry systems designed to measure oxygen sufficiency within organs and veins without the need for invasive catheters. The company's primary focus is on monitoring brain oxygenation in preterm babies within newborn intensive care units (NICUs). Noninvasix has raised over $6.8 million in funding, including a seed round in late 2021, and has been supported by grants from the NIH and DOD totaling $6 million. The company's technology has been clinically validated and is protected by a robust IP portfolio comprising 9 U.S. and 8 global patents. Noninvasix has participated in prestigious accelerator programs such as Philips Healthworks and TMCx, and its innovations have earned multiple awards.
NovaScan
Convertible Note in 2021
NovaScan, Inc. is a medical technology company based in Chicago, Illinois, focused on developing and manufacturing innovative cancer detection devices. Founded by a former Dean of the Engineering School at the University of Wisconsin Milwaukee, the company employs a unique technology based on Cole relaxation frequency to detect and stratify various types of cancer. Its product offerings include MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, and FastScan Probe for identifying breast cancer. In addition, NovaScan provides electrical mammogram technology and a platform capable of detecting multiple cancerous conditions. The company's non-invasive approach is designed to facilitate minimally invasive procedures and enhance therapeutic dosing into live tumors, ultimately aiming to improve patient outcomes while reducing healthcare costs. NovaScan was originally incorporated as EPET, LLC in 2001.
Worlds, Inc., established in 2018 and based in Dallas, Texas, specializes in spatial artificial intelligence (AI) solutions. The company's flagship product, SpatialSense, is a comprehensive platform that combines deep learning and IoT within a 4D environment. SpatialSense enables organizations to remotely monitor and analyze their physical spaces, providing insights into people, objects, and events. The platform includes modules for AI training, 3D modeling, spatial navigation, and AI bot creation. Worlds serves clients in military, healthcare, and energy sectors, helping them optimize their operations through real-world automation.
OneDay is a Texas-based software-as-a-service company that specializes in video storytelling technology aimed at enhancing revenue growth and customer engagement for businesses. Its platform provides an online application that enables organizations, particularly in the senior living sector, to create customizable branded video content at scale. By utilizing question-and-answer prompts, OneDay's technology helps clients increase resident engagement and improve customer satisfaction, offering effective digital marketing opportunities.
Ataia Medical
Seed Round in 2018
Ataia Medical, established in 2017 by biomedical engineers and critical care physicians, focuses on creating innovative communication solutions for patients who are unable to speak due to the use of hard plastic hospital masks. The company develops a medical device and communication system that facilitates interaction between patients and their physicians, caregivers, and family members. This intuitive communication aid enables patients undergoing non-invasive ventilation and oxygen therapies in critical care settings to effectively convey their needs and thoughts, thereby enhancing their overall care experience.
Gregor Diagnostics
Seed Round in 2018
Gregor Diagnostics Inc. is a molecular diagnostics company dedicated to developing innovative screening tests for prostate cancer. Founded in 2016 and headquartered in Madison, Wisconsin, the company has created a technology that utilizes seminal fluid as a sample source. This advanced testing method enables the early detection of prostate cancer and helps differentiate between indolent and aggressive forms of the disease. By providing a reliable assessment of cancer aggressiveness, Gregor Diagnostics aims to assist physicians in reducing the risks of overdiagnosis and overtreatment of less severe cases while enhancing the management of more aggressive prostate cancer.
CounterFind
Seed Round in 2017
CounterFind Inc. is a technology company based in Dallas, Texas, that specializes in developing software aimed at tracking and eliminating counterfeit products marketed online. Founded in 2016, the company offers a turnkey brand protection solution that integrates a proprietary filtering algorithm with industry expertise. This software effectively identifies, reports, and removes advertisements for counterfeit merchandise on social media platforms such as Facebook, as well as counterfeit listings on online marketplaces like Amazon, all in real-time. By employing advanced image recognition technology, CounterFind enables brands to safeguard their reputation and maintain the integrity of their products in the digital marketplace.
Thermalin
Series A in 2017
Thermalin, Inc. is a biotechnology company based in Cleveland, Ohio, founded in 2010, that focuses on developing innovative insulin therapies for individuals with Type 1 and Type 2 diabetes. The company aims to transform the insulin and insulin delivery market, valued at $30 billion, through its cutting-edge, highly concentrated, ultra-rapid acting insulin and a novel glucose management system that is the size of a postage stamp. This insulin can also be utilized in existing insulin pumps, enhancing their efficiency. In addition to its lead program, Thermalin is exploring partnerships to create no-cold-chain basal and mix insulins, as well as glucose-responsive insulins. Its products are designed to be rapidly absorbing and do not require refrigeration, thereby reducing the burden of insulin therapy and improving patient adherence and health outcomes.
Take Command
Seed Round in 2017
Take Command Health is a health insurance software provider that focuses on assisting small businesses and independent professionals in managing their health insurance needs. The company offers an innovative platform that allows small employers to reimburse employees tax-free for health insurance and medical expenses through a small business health reimbursement arrangement. By providing unbiased health plan recommendations and utilizing advanced plan choice software, Take Command Health empowers employers and employees to make informed decisions regarding health insurance. The company aims to simplify the health insurance process for small businesses while enhancing the overall experience for consumers.
Meta SaaS
Seed Round in 2017
Meta SaaS, Inc. is a software as a service (SaaS) provider based in Austin, Texas, specializing in vendor management solutions for small and medium-sized businesses. Established in 2016, the company offers a comprehensive platform that helps organizations monitor and manage their SaaS subscriptions. Its software consolidates vendor information into a single dashboard, allowing users to identify and eliminate unnecessary SaaS expenditures. Meta SaaS ensures PCI compliance and connects with various expense, accounting, and payment vendors to streamline operations. The solution tracks contract dates, adjusts reminders based on contract value, and monitors license utilization across all SaaS applications. By providing detailed reports, Meta SaaS enables procurement, IT, and finance teams to gain visibility into application usage, ultimately facilitating better decision-making and cost management. As of 2018, Meta SaaS operates as a subsidiary of Flexera Software LLC.
Semler Scientific
Post in 2017
Semler Scientific, Inc. is a medical technology company based in San Jose, California, focused on developing, manufacturing, and marketing proprietary products designed to assist healthcare providers in evaluating and treating chronic diseases. Founded in 2007, the company offers innovative solutions such as QuantaFlo, a quick in-office blood flow test that enables healthcare providers to assess patients' vascular conditions effectively. Semler's products cater to a diverse range of medical professionals, including cardiologists, nephrologists, and primary care physicians, as well as healthcare insurance plans and integrated delivery networks. The company aims to enhance the clinical effectiveness and efficiency of healthcare delivery while ensuring that providers can fully capture reimbursement for their services. With a commitment to advancing medical risk assessment, Semler Scientific is recognized for its contributions to improving patient care in the United States.
Ortho Kinematics
Venture Round in 2017
Ortho Kinematics, Inc. is a healthcare diagnostics company based in Austin, Texas, specializing in spine imaging informatics. Founded in 2006, the company develops innovative diagnostic technology solutions for assessing spinal health. Its flagship product, the KineGraph Vertebral Motion Analyzer, employs fluoroscopy to capture spine motion and produce detailed patient-specific graphs that assist clinicians in diagnosing spinal instability and related conditions. In addition to its diagnostic devices, Ortho Kinematics offers comprehensive spine diagnostic imaging services through its imaging center in Austin, providing valuable information to healthcare professionals for the effective treatment of back and neck pain.
Simpirica Spine
Series A in 2017
Simprica Spine is a stabilization system designed to stabilize the spine in flexion and helps patients rehabilitate better.
Orb Health
Series A in 2016
Orb Health, Inc. is a mobile healthcare technology company based in Richardson, Texas, that specializes in personalized healthcare solutions for physicians, employers, clinical laboratories, and individuals. The company offers a Collaborative Virtual Care platform that facilitates the delivery of reimbursed Medicare services, including chronic care management, as a virtual extension of existing medical practices. This system integrates with existing electronic medical records (EMR) and enhances clinical workflows, allowing certified remote providers to deliver high-quality care while maintaining the integrity of the practice. By optimizing clinical processes and driving patient engagement, Orb Health enables healthcare providers to improve patient access and outcomes without incurring additional staffing or office space costs. Founded in 2011, Orb Health aims to enhance the efficiency and profitability of healthcare delivery, particularly for Federally Qualified Health Centers, Community Health Centers, health systems, and Accountable Care Organizations.
Archeio Technologies
Seed Round in 2016
Archeio Technologies, LLC is a provider of cloud-based well information management software tailored for the oil and gas industry. The company offers SkyWell, a comprehensive application that enables exploration and production companies to secure, centralize, and manage well data effectively. This software allows engineers, geologists, and landmen to access and search well information from various devices, facilitating better business decisions. In addition to the software solution, Archeio provides a range of support services including on-premise installation, end-user training, data preparation and migrations, technical integration, and ongoing customer support. Founded in 2014 and based in Dallas, Texas, Archeio Technologies operates as a subsidiary of Quorum Business Solutions, Inc.
Potrero Medical
Series A in 2016
Potrero Medical, Inc. is a predictive health company that specializes in developing advanced monitoring devices to detect subtle changes in physiological parameters. The company's products are designed to provide early warnings of conditions such as sepsis and systemic inflammatory response syndrome, while also optimizing treatment by detecting and preventing fluid overload during resuscitation efforts. Potrero Medical's devices monitor various metrics, including intra-abdominal pressure, core body temperature, heart rate, respiratory rate, relative cardiac output, and urine output. Founded in 2011 and based in San Francisco, California, the company aims to leverage smart sensors and artificial intelligence to enhance the ability of medical teams to predict adverse outcomes in critical care environments.
Take Command
Seed Round in 2016
Take Command Health is a health insurance software provider that focuses on assisting small businesses and independent professionals in managing their health insurance needs. The company offers an innovative platform that allows small employers to reimburse employees tax-free for health insurance and medical expenses through a small business health reimbursement arrangement. By providing unbiased health plan recommendations and utilizing advanced plan choice software, Take Command Health empowers employers and employees to make informed decisions regarding health insurance. The company aims to simplify the health insurance process for small businesses while enhancing the overall experience for consumers.
Dignitana
Venture Round in 2016
Dignitana AB is a medical technology company specializing in scalp cooling solutions for cancer patients undergoing chemotherapy. The company has developed the DigniCap® Scalp Cooling System, a patented medical device designed to reduce chemotherapy-induced hair loss. Clinical studies have shown that the DigniCap system is effective, with over eighty percent of patients retaining enough hair to avoid using wigs. By providing this innovative solution, Dignitana aims to enhance the well-being and quality of life for cancer patients during their treatment. The majority of the company's revenue is generated in the United States.
TheraNova LLC.
Venture Round in 2016
TheraNova, LLC is a medical device development company based in Redwood City, California, founded in 2006 by Daniel R. Burnett. The company focuses on creating innovative biomedical device technologies, including low frequency induction therapy, cardiovascular anchors, dynamic vacuum compression systems, and auto-sterilizing implants. Additionally, TheraNova develops a range of other medical devices, such as non-invasive therapies for obesity and incontinence, an implantable shunt for chronic fluid management, therapeutic hypothermia solutions, and breast implants. Beyond product development, TheraNova also serves as an innovation incubator, assisting in clinical development and strategic investments for medical device startups, providing essential resources like research, regulatory support, and business development expertise.
Adient Medical
Series C in 2016
Adient Medical Inc. is a company focused on the development and delivery of absorbable medical devices, specifically designed to prevent pulmonary embolism. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical's flagship product is an absorbable vascular filter that provides an effective solution for patients at risk of this condition. The company operates on the principle that implants should remain safe and effective throughout their useful lifespan and then dissolve without the need for surgical removal, thereby minimizing the risk of complications and reducing healthcare costs associated with removal procedures. Through its innovative approach, Adient Medical aims to enhance patient safety and improve outcomes in vascular care.
PuraCath Medical
Series A in 2016
PuraCath Medical, Inc. is a San Francisco-based company founded in 2010 that focuses on enhancing the quality of life for patients undergoing peritoneal dialysis. The company has developed a disinfection device designed to minimize infectious complications associated with catheter connections. Utilizing proprietary ultraviolet technology, PuraCath's device aims to provide a safe and efficient treatment for dialysis patients while reducing reliance on patient compliance. By simplifying the connection process of peritoneal dialysis catheters, the company seeks to protect patients from infections, ultimately improving their health and overall experience during dialysis.
Xclaim Mobile
Convertible Note in 2016
Xclaim Mobile, Inc. is a Dallas-based company that specializes in developing an enterprise-grade mobile offer platform designed to enhance digital marketing efforts. Founded in 2016, Xclaim offers a solution that streamlines the transition to mobile marketing by providing tools for location-based marketing campaigns. The platform detects users' devices, locations, and wallet types, allowing for customized offers that can be accepted through popular mobile payment systems such as Apple Pay, Android Pay, and Microsoft Wallet. By enabling brands to engage consumers with timely notifications and relevant offers, Xclaim aims to drive customer response and revenue across industries such as telecommunications, consumer lending, automotive, and retail.
Savara Pharmaceuticals
Series C in 2016
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
MicroTransponder
Series C in 2015
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Supergoop
Series A in 2015
Supergoop, LLC is a skincare brand dedicated to sun protection, specializing in a diverse range of products designed to safeguard against ultraviolet (UV) rays. Founded in 2007 and headquartered in San Antonio, Texas, the company offers a variety of items, including sunscreen mousse, serums, CC creams, mineral setting powders, anti-aging eye creams, and lip balms for the face. For the body, it provides products such as hand creams, mineral sunscreen mists, and body butters. The brand also caters to children with specialized lip balms and sunscreens. In addition to its extensive line of mineral products, Supergoop also creates offerings tailored for travelers. The company distributes its products through online platforms and retail stores, making them accessible to a wide audience.
CancerGene Connect
Seed Round in 2015
CancerGene Connect is a developer of a cloud-based genetic assessment platform that focuses on collecting, assessing, and managing genetic family histories. The platform streamlines the genetic counseling process by facilitating the collection of family medical histories and cancer risk assessments. This innovative technology allows clinicians to dedicate more time to addressing patient risks by reducing the time spent on data organization. With ongoing improvements, CancerGene Connect enhances its capabilities in pedigree generation and risk modeling, ultimately benefiting thousands of patients and healthcare practices.
Kickbox
Seed Round in 2015
Kickbox Inc., established in 2015 and headquartered in Dallas, Texas, specializes in email address verification services. As a subsidiary of J2 Global Inc., Kickbox helps businesses maintain email list hygiene by identifying and removing undeliverable, fake, or low-quality addresses. This process enhances email reputation, boosts open rates, and reduces costs associated with bounced emails.
Dignitana
Venture Round in 2015
Dignitana AB is a medical technology company specializing in scalp cooling solutions for cancer patients undergoing chemotherapy. The company has developed the DigniCap® Scalp Cooling System, a patented medical device designed to reduce chemotherapy-induced hair loss. Clinical studies have shown that the DigniCap system is effective, with over eighty percent of patients retaining enough hair to avoid using wigs. By providing this innovative solution, Dignitana aims to enhance the well-being and quality of life for cancer patients during their treatment. The majority of the company's revenue is generated in the United States.
AlgoMedica
Series A in 2015
AlgoMedica Inc., established in 2012 and headquartered in Palo Alto, California, specializes in developing software solutions for medical imaging. Its flagship product, PixelShine, is a server or cloud-based solution that enhances the quality of low-dose CT scan images, enabling radiologists to achieve standard protocol image quality using only 10% of the typical radiation dose. AlgoMedica's technology, based on artificial neural networks, is adaptable for various body parts and applications, including abdomen/pelvis, head, liver, and pediatric imaging.
TheraNova LLC.
Venture Round in 2015
TheraNova, LLC is a medical device development company based in Redwood City, California, founded in 2006 by Daniel R. Burnett. The company focuses on creating innovative biomedical device technologies, including low frequency induction therapy, cardiovascular anchors, dynamic vacuum compression systems, and auto-sterilizing implants. Additionally, TheraNova develops a range of other medical devices, such as non-invasive therapies for obesity and incontinence, an implantable shunt for chronic fluid management, therapeutic hypothermia solutions, and breast implants. Beyond product development, TheraNova also serves as an innovation incubator, assisting in clinical development and strategic investments for medical device startups, providing essential resources like research, regulatory support, and business development expertise.
Admittance Technologies
Series A in 2015
Admittance Technologies, Inc. is a medical technology company based in Austin, Texas, with an additional office in San Antonio. Founded in 2010, the company specializes in developing proprietary software and platform technology aimed at improving the lives of heart failure patients. Its flagship product, CardioVol, utilizes electric fields to assess the heart's condition in real-time, distinguishing between the blood and heart muscle components. This technology enables the monitoring of critical hemodynamic data, such as left ventricular end-diastolic volume, and helps optimize pacemaker function using existing bi-ventricular leads. By focusing on the blood signals, Admittance Technologies aims to provide early warnings of impending heart failure, enhance the heart's pumping efficiency, and guide treatment decisions for conditions like ventricular tachycardia and rapid atrial fibrillation.
Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.
InterVene
Series A in 2015
InterVene is a medical device company focused on innovating treatments for chronic venous disease, particularly deep vein valve failure. The company develops catheter-based, non-implantable therapies designed to restore valvular competency in the deep veins affected by chronic venous insufficiency. Its BlueLeaf Endovenous Valve Formation System is described as a non-implantable solution to create new vein valves from the patient's own vein wall tissue, enabling minimally invasive treatment for conditions such as venous stasis ulcers and related symptoms. Founded in 2011 and based in South San Francisco, California, InterVene aims to improve valve function and blood flow in legs through catheter-based approaches that avoid implants.
Orb Health
Seed Round in 2015
Orb Health, Inc. is a mobile healthcare technology company based in Richardson, Texas, that specializes in personalized healthcare solutions for physicians, employers, clinical laboratories, and individuals. The company offers a Collaborative Virtual Care platform that facilitates the delivery of reimbursed Medicare services, including chronic care management, as a virtual extension of existing medical practices. This system integrates with existing electronic medical records (EMR) and enhances clinical workflows, allowing certified remote providers to deliver high-quality care while maintaining the integrity of the practice. By optimizing clinical processes and driving patient engagement, Orb Health enables healthcare providers to improve patient access and outcomes without incurring additional staffing or office space costs. Founded in 2011, Orb Health aims to enhance the efficiency and profitability of healthcare delivery, particularly for Federally Qualified Health Centers, Community Health Centers, health systems, and Accountable Care Organizations.
Vapogenix
Series B in 2015
Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, that specializes in the development of non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company focuses on creating products that utilize formulated volatile anesthetics, which differ from traditional unformulated volatile anesthetics currently used only for general anesthesia. Vapogenix's product line is designed to alleviate pain associated with venipuncture, venous cannulation, and minor dermatological procedures, as well as to manage pain related to wound care and localized inflammation. By improving the pain management experience for patients, particularly hospitalized children undergoing venous access procedures, Vapogenix aims to enhance the efficiency and effectiveness of healthcare providers in their practices.
Lantern Pharma
Funding Round in 2015
Lantern Pharma Inc. is a clinical-stage biotechnology company based in Dallas, Texas, specializing in the development of precision oncology therapeutics through the integration of artificial intelligence, genomics, and machine learning. The company's lead drug candidate, LP-100, is currently undergoing phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. Additionally, Lantern is advancing LP-300 as a combination therapy for female non-smokers with non-small cell lung cancer adenocarcinoma. Another promising candidate in preclinical development is LP-184, an alkylating agent targeting DNA in cancer cells that overexpress specific biomarkers. Lantern Pharma employs its proprietary RADR platform to enhance drug discovery and development, addressing challenges in patient stratification and understanding mechanisms of action, ultimately aiming to accelerate the delivery of personalized cancer therapies. The company was incorporated in 2013 and has positioned itself at the forefront of innovation in oncology.
Retrotope
Series B in 2015
Retrotope Inc. is a biotechnology company based in Los Altos, California, focused on developing innovative therapeutics for degenerative diseases. Founded in 2006, Retrotope specializes in preserving and restoring mitochondrial health, addressing conditions associated with oxidative stress. The company’s primary therapeutic candidates target a range of neurological disorders, including Parkinson's disease, Alzheimer's disease, and specific mitochondrial myopathies. Notably, Retrotope is developing RT001, a drug aimed at treating infantile neuroaxonal dystrophy. Through its unique drug platform, Retrotope employs isotope effects to mitigate cellular damage caused by lipid peroxidation, positioning itself as a leader in the treatment of intractable and degenerative disorders. The company engages in multiple discovery and development programs, emphasizing its commitment to advancing healthcare solutions for challenging neurological conditions.
Ikonopedia
Series B in 2014
Ikonopedia, LLC is a developer of a cloud-based breast study interpretation and reporting system designed to enhance the efficiency of radiologists. Established in 2012 and headquartered in Dallas, Texas, the company provides a comprehensive Mammography Reporting System that ensures compliance with the Mammography Quality Standards Act (MQSA) and offers customizable report macros for individual practitioners. Additionally, Ikonopedia's SonoPro application supports radiologists during diagnostic breast ultrasound exams. The solutions are designed to automate tracking and monitoring of patients, ensuring clear and consistent clinical reports that adhere to the ACR BI-RADS® Atlas 5th Edition. The system is compatible with various modern devices and is utilized by telemammography and satellite clinics, ultimately aiming to improve patient safety, streamline workflows, and enhance the overall experience for radiologists and their staff.
Silicone Arts Laboratories
Seed Round in 2014
Silicone Arts Laboratories, LLC is a Memphis, Tennessee-based company founded in 2010, specializing in the manufacture of cosmetic products aimed at enhancing physical appearances. The company is best known for its flagship product, Dermaflage, a topical scar filler that effectively conceals recessed scars and skin defects on both the face and body without the need for surgery or injections. Utilizing silicone to replicate the tone and texture of natural skin, Dermaflage offers a practical solution for individuals seeking to hide imperfections resulting from various conditions, including acne, chickenpox, bite marks, and surgical scars. In addition to Dermaflage, Silicone Arts Laboratories develops AeXP (Anatomical Eye – Experimental), a precise replica of a human eye designed for medical training and device testing.
Socrates Health Solutions
Series A in 2014
Socrates Health Solutions, Inc. is a Dallas-based company that develops and manufactures innovative diabetes testing devices. Their flagship product, the Companion, is a non-invasive self-monitoring device that enables users to measure blood glucose levels without the need for needles or finger pricks. This technology provides real-time data to help individuals manage their diabetes effectively, generating custom alerts for critical glucose levels and facilitating communication with mobile devices to track historical data. Founded in 2013, Socrates Health Solutions aims to enhance access to affordable diabetes care through advanced technology, allowing patients to make informed treatment decisions and reduce complications associated with the disease.
E-Nicotine Technology
Series A in 2014
E-Nicotine Technology, Inc. is a healthcare company based in Draper, Utah, that specializes in developing electronic nicotine delivery products aimed at helping smokers transition from traditional cigarettes. Founded in 2012, the company focuses on creating devices that provide precise doses of nicotine through aerosols designed for deep lung delivery, effectively addressing cravings while minimizing exposure to harmful substances found in cigarette smoke. By leveraging a regulatory pathway established by the Center for Tobacco Products at the FDA, E-Nicotine Technology aims to bring its products to market efficiently and safely. The management team possesses extensive expertise in areas such as aerosolization, pulmonary drug delivery, and addiction, positioning the company to make significant advancements in nicotine delivery technology. As a subsidiary of Fontem Ventures B.V., E-Nicotine Technology is committed to providing smokers with safer alternatives for nicotine consumption.
AdBm Technologies
Series A in 2014
AdBm Technologies is an acoustical engineering company that develops underwater noise abatement solutions for marine environments. It focuses on environmental engineering, marine technology, and mechanical engineering, and employs arrays of Helmholtz resonators tuned to specific frequencies to capture and reduce noise from industrial operations at sea, with the goal of protecting marine wildlife. Founded in 2012, the company is based in Austin, Texas.
Channel Medsystems
Series C in 2014
Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.
Nasseo, Inc. is a medical device company based in Peoria, Arizona, that specializes in the development and manufacturing of dental and orthopedic implant systems. Founded in 2012, Nasseo has pioneered a next-generation nanotube implant surface technology known as TiArray, which enhances the performance of implants for patients with poor circulatory issues, such as diabetics and smokers. This innovative technology modifies the natural oxide layer of implant materials, resulting in a uniform nanotube array that promotes stronger bonding, faster healing, and improved tissue response. Nasseo's flagship product, the TiArray Dental Implant, has received FDA approval, and the company plans to conduct post-market human clinical trials. Additionally, Nasseo is working on a Titanium-PEEK hybrid interbody fusion device that will also incorporate its advanced TiArray technology, further expanding its product offerings in the field of implantable medical devices.
Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.
Savara Pharmaceuticals
Series C in 2014
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Cariloop
Seed Round in 2014
Cariloop, Inc. is a Dallas-based company that offers a digital platform designed to assist seniors and their caregivers in managing care needs. Founded in 2012, the platform connects families with various senior care services, including assisted living, Alzheimer care, hospice, and home health care. It features tools that allow care providers to market their services, share real-time information, and track engagement data. Cariloop also provides access to experienced Care Coaches who offer personalized support and guidance, helping users navigate the complexities of caregiving. By streamlining the process of finding and coordinating care, Cariloop aims to reduce stress for caregivers while enhancing the overall caregiving experience.
Ortho Kinematics
Venture Round in 2014
Ortho Kinematics, Inc. is a healthcare diagnostics company based in Austin, Texas, specializing in spine imaging informatics. Founded in 2006, the company develops innovative diagnostic technology solutions for assessing spinal health. Its flagship product, the KineGraph Vertebral Motion Analyzer, employs fluoroscopy to capture spine motion and produce detailed patient-specific graphs that assist clinicians in diagnosing spinal instability and related conditions. In addition to its diagnostic devices, Ortho Kinematics offers comprehensive spine diagnostic imaging services through its imaging center in Austin, providing valuable information to healthcare professionals for the effective treatment of back and neck pain.
ImageVision
Series B in 2014
ImageVision specializes in visual content recognition and monetization for social media and multimedia platforms. It offers real-time, AI-driven technology that identifies and categorizes billions of daily photos and videos, enabling clients like Apple, Facebook, and Yahoo! to enhance image search, analyze brands, tailor ads, and safeguard against inappropriate content. The company's platform also provides facial recognition and demographic insights, helping clients improve operational efficiency and brand protection.
Tractus Corporation is a technology company specializing in cancer detection for women, focusing on developing innovative hardware and software solutions. Based in Austin, Texas, the company addresses the critical need for affordable ultrasound systems specifically designed for whole breast imaging. Its flagship product, the BreastMapper, features a unique accessory probe that attaches to standard ultrasound machines and integrates with a proprietary software suite, streamlining the review and reporting process of breast scans. This system significantly enhances the detection of small, treatable breast cancers, particularly in women with dense breast tissue, serving as an adjunct to traditional mammography. Founded in 2012, Tractus aims to improve early cancer detection and diagnosis through its advanced technological offerings.
Make My plate
Angel Round in 2014
Make My Plate is changing the dieting world! They present a visually appealing and fun approach to maintaining a healthy lifestyle. They are connecting the dietary ecosystem, answering the user's nutritional needs on one hand and creating a marketplace for professionals on the other.
Vapogenix
Series B in 2013
Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, that specializes in the development of non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company focuses on creating products that utilize formulated volatile anesthetics, which differ from traditional unformulated volatile anesthetics currently used only for general anesthesia. Vapogenix's product line is designed to alleviate pain associated with venipuncture, venous cannulation, and minor dermatological procedures, as well as to manage pain related to wound care and localized inflammation. By improving the pain management experience for patients, particularly hospitalized children undergoing venous access procedures, Vapogenix aims to enhance the efficiency and effectiveness of healthcare providers in their practices.
Socrates Health Solutions
Series A in 2013
Socrates Health Solutions, Inc. is a Dallas-based company that develops and manufactures innovative diabetes testing devices. Their flagship product, the Companion, is a non-invasive self-monitoring device that enables users to measure blood glucose levels without the need for needles or finger pricks. This technology provides real-time data to help individuals manage their diabetes effectively, generating custom alerts for critical glucose levels and facilitating communication with mobile devices to track historical data. Founded in 2013, Socrates Health Solutions aims to enhance access to affordable diabetes care through advanced technology, allowing patients to make informed treatment decisions and reduce complications associated with the disease.
Tractus Corporation is a technology company specializing in cancer detection for women, focusing on developing innovative hardware and software solutions. Based in Austin, Texas, the company addresses the critical need for affordable ultrasound systems specifically designed for whole breast imaging. Its flagship product, the BreastMapper, features a unique accessory probe that attaches to standard ultrasound machines and integrates with a proprietary software suite, streamlining the review and reporting process of breast scans. This system significantly enhances the detection of small, treatable breast cancers, particularly in women with dense breast tissue, serving as an adjunct to traditional mammography. Founded in 2012, Tractus aims to improve early cancer detection and diagnosis through its advanced technological offerings.
Maui Imaging
Series B in 2013
Maui Imaging, Inc. is a manufacturer of advanced ultrasound imaging devices, established in 2006 and headquartered in Sunnyvale, California. The company specializes in producing multiple aperture ultrasound systems that provide enhanced imaging capabilities, allowing for the visualization of structures such as bones, metals, plastics, gas, and soft tissue. Utilizing innovative technologies like Computed Echo Tomography and adaptive beam forming, Maui Imaging's devices deliver 3D imaging that surpasses the capabilities of traditional ultrasound methods. This advanced imaging technology supports healthcare providers in making more accurate diagnoses and treatment decisions.
Brainspace
Series C in 2013
Brainspace Corporation specializes in eDiscovery software and unstructured data analytics, focusing on information governance and compliance solutions for enterprise clients, including general counsel offices, law firms, and litigation service providers. Founded in 2005 and headquartered in Dallas, Texas, Brainspace has established itself as a leader in the industry by offering innovative products that utilize a patented platform for text analytics. Their solutions enable organizations to discover, collect, and share content effectively, facilitating the extraction of insights and identification of human connections within complex data sets. Key offerings include Brainspace Discovery, which features visual analytics and intelligent search capabilities, and Brainspace Discovery On-Demand, providing flexible access to eDiscovery tools. The company serves a diverse clientele, including Fortune 500 companies, consulting firms, legal service providers, and government agencies, enhancing their ability to manage and analyze unstructured data.
E-Nicotine Technology
Series A in 2013
E-Nicotine Technology, Inc. is a healthcare company based in Draper, Utah, that specializes in developing electronic nicotine delivery products aimed at helping smokers transition from traditional cigarettes. Founded in 2012, the company focuses on creating devices that provide precise doses of nicotine through aerosols designed for deep lung delivery, effectively addressing cravings while minimizing exposure to harmful substances found in cigarette smoke. By leveraging a regulatory pathway established by the Center for Tobacco Products at the FDA, E-Nicotine Technology aims to bring its products to market efficiently and safely. The management team possesses extensive expertise in areas such as aerosolization, pulmonary drug delivery, and addiction, positioning the company to make significant advancements in nicotine delivery technology. As a subsidiary of Fontem Ventures B.V., E-Nicotine Technology is committed to providing smokers with safer alternatives for nicotine consumption.
MicroTransponder
Venture Round in 2013
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Supergoop
Series A in 2013
Supergoop, LLC is a skincare brand dedicated to sun protection, specializing in a diverse range of products designed to safeguard against ultraviolet (UV) rays. Founded in 2007 and headquartered in San Antonio, Texas, the company offers a variety of items, including sunscreen mousse, serums, CC creams, mineral setting powders, anti-aging eye creams, and lip balms for the face. For the body, it provides products such as hand creams, mineral sunscreen mists, and body butters. The brand also caters to children with specialized lip balms and sunscreens. In addition to its extensive line of mineral products, Supergoop also creates offerings tailored for travelers. The company distributes its products through online platforms and retail stores, making them accessible to a wide audience.
Natural Dental Implants
Series A in 2013
Natural Dental Implants AG, founded in 2006 and based in Berlin, Germany, specializes in the manufacture of non-surgical tooth replacement systems. The company focuses on creating innovative solutions for dental restoration, offering patented products that facilitate tooth replacement without the need for drilling or compromising healthy teeth. This minimally invasive approach aims to enhance patient comfort and preserve dental integrity, positioning Natural Dental Implants as a leader in the field of dental technology.
Ikonopedia
Series A in 2013
Ikonopedia, LLC is a developer of a cloud-based breast study interpretation and reporting system designed to enhance the efficiency of radiologists. Established in 2012 and headquartered in Dallas, Texas, the company provides a comprehensive Mammography Reporting System that ensures compliance with the Mammography Quality Standards Act (MQSA) and offers customizable report macros for individual practitioners. Additionally, Ikonopedia's SonoPro application supports radiologists during diagnostic breast ultrasound exams. The solutions are designed to automate tracking and monitoring of patients, ensuring clear and consistent clinical reports that adhere to the ACR BI-RADS® Atlas 5th Edition. The system is compatible with various modern devices and is utilized by telemammography and satellite clinics, ultimately aiming to improve patient safety, streamline workflows, and enhance the overall experience for radiologists and their staff.
SendInc
Seed Round in 2013
SendInc is a developer of a SaaS-based electronic messaging and collaboration platform that specializes in providing secure email services. The company's platform employs advanced email encryption methodologies to ensure that communications are secure and compliant with various regulations, including HIPAA, GLBA, SOX, and PCI-DSS. Targeting small to medium-sized businesses, professionals, non-profit organizations, and individuals, SendInc enables its users to maintain the highest standards of message encryption. By integrating secure email capabilities into web and software applications, SendInc supports organizations in navigating the complexities of regulatory compliance while safeguarding sensitive information.
MicroTransponder
Venture Round in 2013
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Tractus
Seed Round in 2013
Tractus Corporation is a technology company specializing in cancer detection for women, focusing on developing innovative hardware and software solutions. Based in Austin, Texas, the company addresses the critical need for affordable ultrasound systems specifically designed for whole breast imaging. Its flagship product, the BreastMapper, features a unique accessory probe that attaches to standard ultrasound machines and integrates with a proprietary software suite, streamlining the review and reporting process of breast scans. This system significantly enhances the detection of small, treatable breast cancers, particularly in women with dense breast tissue, serving as an adjunct to traditional mammography. Founded in 2012, Tractus aims to improve early cancer detection and diagnosis through its advanced technological offerings.
Perio Sciences
Venture Round in 2012
Perio Sciences, LLC is a Dallas-based company that specializes in the development of oral healthcare products. Founded in 2008, the company offers a range of products including dental gels, mouth rinses, toothpastes, and comprehensive oral care systems. These products are distributed through various channels, including dental professionals, hygienists, specialists, other medical practitioners, medi-spas, and online platforms. Perio Sciences is committed to enhancing oral health through innovative solutions tailored for both professional and consumer use.
TangoTab, Inc. is a mobile application developer based in Dallas, Texas, focused on combating local hunger in the United States. Founded in 2010, TangoTab connects consumers with nearby restaurants, offering exclusive deals when users check in or redeem offers at participating establishments. Through this model, each meal that is purchased prompts a donation to a local food bank, ensuring that every transaction contributes to feeding individuals in need. The application serves as a yield-management solution for restaurants, helping them attract customers during off-peak times while simultaneously facilitating a philanthropic effort. By using TangoTab, both consumers and restaurants actively participate in supporting their communities.
Order Mapper
Seed Round in 2012
Order Mapper Inc. is a Platform as a Service ("PaaS") startup founded in 2009. We make it easy for people to order virtually any physical good or service from almost any business from a mobile device such as a smartphone or tablet. Our cloud-based platform receives, processes, and delivers orders to businesses, providing targeted marketing and promotional opportunities. Our app 'Order Pizza' for iPhone is the largest independent pizza directory on mobile. We’ve fulfilled orders for over 30% of pizzerias in the United States, gaining over 250,000 downloads in the process and placing as one of the Top 100 Lifestyle apps in the App Store. We secured early investment from 500 Startups (Dave McClure) and were recently accepted into Tech Wildcatters (class of Spring 2012), one of the Top 10 business accelerators in the United States. We've been featured on TechCrunch, MacWorld, VentureBeat and Geekwire.
MobileLutions
Seed Round in 2012
MobileLutions, LLC is a software company based in Dallas, Texas, that specializes in solutions aimed at preventing driving accidents and minimizing corporate liability associated with distracted driving. Founded in 2010, the company offers an application called MobiLoc, designed to disable texting and other mobile phone functionalities while driving. MobiLoc is available in two versions: a free version that blocks texting when the vehicle exceeds 7 mph for 20 seconds and allows access after a brief idle period, and a paid version that additionally restricts email, social media, and internet browsing. The paid version also features a passenger mode, permitting temporary access to the phone's functions if the user is not driving. MobileLutions’ solutions are compatible with most smartphones, including iPhones and Android devices, and require no hardware installation, making them accessible for a wide range of users.
Semler Scientific
Venture Round in 2012
Semler Scientific, Inc. is a medical technology company based in San Jose, California, focused on developing, manufacturing, and marketing proprietary products designed to assist healthcare providers in evaluating and treating chronic diseases. Founded in 2007, the company offers innovative solutions such as QuantaFlo, a quick in-office blood flow test that enables healthcare providers to assess patients' vascular conditions effectively. Semler's products cater to a diverse range of medical professionals, including cardiologists, nephrologists, and primary care physicians, as well as healthcare insurance plans and integrated delivery networks. The company aims to enhance the clinical effectiveness and efficiency of healthcare delivery while ensuring that providers can fully capture reimbursement for their services. With a commitment to advancing medical risk assessment, Semler Scientific is recognized for its contributions to improving patient care in the United States.
EdgePoint Power
Seed Round in 2012
Demand Response programs are becoming an integral component of the evolving smart grid infrastructure. Large commercial building owners and operators are beginning to realize new sources of revenue available for their willingness to shed energy load during periods of peak consumption. Tenant comfort remains a primary concern for owners and operators; however, EdgePoint minimizes those concerns by providing a robust solution that ensures compliance with demand response events while maintaining comfort levels.
Savara Pharmaceuticals
Series B in 2012
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
MicroTransponder
Series B in 2012
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.
Natural Dental Implants
Series A in 2012
Natural Dental Implants AG, founded in 2006 and based in Berlin, Germany, specializes in the manufacture of non-surgical tooth replacement systems. The company focuses on creating innovative solutions for dental restoration, offering patented products that facilitate tooth replacement without the need for drilling or compromising healthy teeth. This minimally invasive approach aims to enhance patient comfort and preserve dental integrity, positioning Natural Dental Implants as a leader in the field of dental technology.
SendInc
Seed Round in 2012
SendInc is a developer of a SaaS-based electronic messaging and collaboration platform that specializes in providing secure email services. The company's platform employs advanced email encryption methodologies to ensure that communications are secure and compliant with various regulations, including HIPAA, GLBA, SOX, and PCI-DSS. Targeting small to medium-sized businesses, professionals, non-profit organizations, and individuals, SendInc enables its users to maintain the highest standards of message encryption. By integrating secure email capabilities into web and software applications, SendInc supports organizations in navigating the complexities of regulatory compliance while safeguarding sensitive information.
Serene Medical
Series A in 2012
Serene Medical Inc., founded in 2010 and based in San Ramon, California, is a medical device company specializing in neurotoxin-free procedures to inhibit motor nerves. Their flagship product, the NeuBelle system (formerly known as GFx), uses radio frequency technology to precisely locate and interrupt nerve signals, providing long-lasting results for patients. This system is particularly used by physicians to treat motor nerves controlling facial expressions, such as frown lines. The company's technology offers a minimally invasive alternative to traditional surgical methods, providing both patients and physicians with new treatment options and revenue streams.
Hie Electronics
Series A in 2012
Hie Electronics, Inc. is a technology company based in McKinney, Texas, specializing in the development and implementation of dense Blu-ray multi-tiered optical data storage units and enterprise-class digital video recorders. Founded in 2004, the company offers its flagship product, the TeraStack Solution, which provides comprehensive data backup and disaster recovery capabilities across various sectors. This innovative solution supports online enterprise application hosting and scalable data storage, accommodating both online and offline needs. Hie Electronics' systems are utilized in critical applications such as medical data retention, video surveillance, cyber forensics, and digital asset management. Their technology enables organizations to efficiently manage and archive large volumes of data while ensuring reliable and affordable storage solutions.
DxUpClose
Seed Round in 2012
DxUpClose, Inc. is an innovative company focused on developing a point-of-care diagnostic device aimed at performing antibiotic sensitivity tests within sixty minutes. Their product utilizes electronic sensor technology to identify specific bacteria, enabling healthcare professionals to diagnose infections at early stages. The device is engineered to count the bacteria present in a sample, even if the intended bacteria are not detectable, and subsequently determine the most effective antibiotics for treatment. At the conclusion of the test, results are securely sent to the healthcare provider's email or smartphone, facilitating prompt interpretation and enabling timely prescriptions. Designed for portability and ease of use, the device weighs less than sixteen ounces, fits in a pocket, operates on batteries, and is resilient in extreme temperatures, ensuring reliable diagnostics in various settings. Overall, DxUpClose aims to significantly reduce the delay in optimal patient care, which typically ranges from one to three days, thereby enhancing treatment outcomes.
Ortho Kinematics
Series B in 2011
Ortho Kinematics, Inc. is a healthcare diagnostics company based in Austin, Texas, specializing in spine imaging informatics. Founded in 2006, the company develops innovative diagnostic technology solutions for assessing spinal health. Its flagship product, the KineGraph Vertebral Motion Analyzer, employs fluoroscopy to capture spine motion and produce detailed patient-specific graphs that assist clinicians in diagnosing spinal instability and related conditions. In addition to its diagnostic devices, Ortho Kinematics offers comprehensive spine diagnostic imaging services through its imaging center in Austin, providing valuable information to healthcare professionals for the effective treatment of back and neck pain.